Allergan announces launch of LILETTA program

Allergan recently announced the launch of its innovative new program, LILETTA + LILETTA Patient Commitment Program, which will allow patients who are eligible the opportunity to acquire a second LILETTA at no cost to them.

LILETTA is a birth control system placed in a woman’s uterus that releases hormones to prevent women from becoming pregnant for up to three years. The product is more than 99 percent effective. Allergan’s new LILETTA + LILETTA Patient Commitment Program was developed for patients that have commercial insurance and received LILETTA on or before Dec. 31 of this year. After three years, eligible patients who want to stay with LILETTA will be able to receive a second product at no cost to them. By joining the program, patients will save up to $700.

Allergan originally released LILETTA in collaboration with Medicines360, a worldwide nonprofit pharmaceutical company that produces medication for women despite their social or economic standing, insurance status or location. The announcement of the LILETTA + LILETTA program last week is part of Allergan’s dedication to increasing access to LILETTA and cutting the cost of the product. The new program is just one of the support programs created by Allergan to help patients.